Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 85% confidence The document is the full text of Daewon Pharmaceutical’s 분기보고서 (Quarterly Report) covering the first quarter of fiscal year 2026 (January 1 to March 31, 2026). It includes extensive sections on company overview, business activities, financial and operational data, capital changes, and detailed quarterly performance metrics. It is not a brief announcement or certification but a comprehensive interim financial report. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a formal notification to the Financial Services Commission/Korea Exchange detailing the appointment of a new outside director (“사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고”), including names, dates, and term details. This clearly describes changes in the board of directors rather than a financial report, earnings release, or other category. Therefore it falls under the Board/Management Information category.
2026-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document provides the official resolutions and voting outcome of the Annual General Meeting held on 2026-03-26, including approval of financial statements, dividend resolutions, and election of directors with detailed voting percentages. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-03-26 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Daewon Pharmaceutical Co., Ltd. for the 65th fiscal year (2025). It contains comprehensive financial data, business operations, management information, and governance details, which is the standard format for an annual report in the South Korean regulatory system (DART). It is not an announcement of a report, but the report itself. FY 2025
2026-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides a summary of the audit opinion (unqualified/proper) and key financial data (assets, liabilities, equity, profit/loss) for both consolidated and separate financial statements. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report document itself. Therefore, it fits the 'AR' (Audit Report / Information) category as it specifically reports the audit results and opinion. FY 2025
2026-03-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share acquisition (insider trading) by an executive (Hanil Lim) of Daewon Pharmaceutical. This falls under the category of Director's Dealing (DIRS).
2026-03-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.